Abstract
Background Identification of individuals with prediabetes who are at high risk of developing diabetes allows for precise interventions. We aimed to determine the role of nuclear magnetic resonance (NMR)-based metabolomic signature in predicting the progression from prediabetes to diabetes.
Methods This prospective study included 13,489 participants with prediabetes who had metabolomic data from the UK Biobank. Circulating metabolites were quantified via NMR spectroscopy. Cox proportional hazard (CPH) models were performed to estimate the associations between metabolites and diabetes risk. Supporting vector machine, random forest, and extreme gradient boosting were used to select the optimal metabolite panel for prediction. CPH and random survival forest (RSF) models were utilized to validate the predictive ability of the metabolites.
Results During a median follow-up of 13.6 years, 2,525 participants developed diabetes. After adjusting for covariates, 94 of 168 metabolites were associated with risk of progression to diabetes. A panel of nine metabolites, selected by all three machine learning algorithms, was found to significantly improve diabetes risk prediction beyond conventional risk factors in the CPH model (area under the receiver operating characteristic curve [AUROC], 1-year: 0.823 for risk factors + metabolites vs 0.759 for risk factors, 5-year: 0.830 vs 0.798, 10-year: 0.801 vs 0.776, all P <0.05). Similar results were observed from the RSF model. Categorization of participants according to the predicted value thresholds revealed distinct cumulative risk of diabetes.
Conclusions Our study lends support for use of the metabolite markers to help determine individuals with prediabetes who are at high risk of progressing to diabetes and inform targeted and efficient interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Shanghai Municipal Health Commission (2022XD017). Innovative Research Team of High-level Local Universities in Shanghai (SHSMU-ZDCX20212501). Shanghai Municipal Human Resources and Social Security Bureau (2020074). Clinical Research Plan of Shanghai Hospital Development Center (SHDC2020CR4006). Science and Technology Commission of Shanghai Municipality (22015810500).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Northwest Multicenter Research Ethics Committee (REC reference for UK Biobank 11/NW/0382), and all participants provided informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: Shanghai Municipal Health Commission (2022XD017). Innovative Research Team of High-level Local Universities in Shanghai (SHSMU-ZDCX20212501). Shanghai Municipal Human Resources and Social Security Bureau (2020074). Clinical Research Plan of Shanghai Hospital Development Center (SHDC2020CR4006). Science and Technology Commission of Shanghai Municipality (22015810500).
Author and author affiliations updated.
Details about covariates collection were removed from the section on Methods to Supplemental files.
Section on Methods updated to clarify the reasons for choosing the top 20 variables in the metabolite selection and the meaning of the decision curve analysis.
Section on Discussion to add the specific names of the metabolites, the limitations of the NMR platform in the UK Biobank, the potential influence of non-fasting status on the findings, the association observed in this study needed to be further validated, and the strength of NMR in metabolic profiling.
Conclusion updated.
Figure 2 revised.
Supplemental files updated to add a more detailed description of parameters tunning and the range of parameters explored during the training of the RSF model, a more detailed description of parameters tunning and the range of parameters explored during the training of the RSF model, and an additional cumulative hazard plot after considering the competing risk from death.
Availability of data and materials
The data analyzed during this study are available at https://www.ukbiobank.ac.uk/. This research has been conducted using the UK Biobank Resource under application number 77740.
